Nonurinary sodium excretion in afebrile cirrhotic patients without diarrhea is approximately 10 mmol/day. [13] Patients with ascites on no diuretics commonly have renal sodium excretion of < 20 ...

About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including ...

The Phase III programme is expected to begin by the end of 2024 and is aiming to include a minimum of 1,800 patients.

The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated ...

Beyond the rise in Nrf2, C. molmol resin treatment also reduced protein tumour necrosis factor-alpha (TNF-α), which is known to be high in the serum of cirrhotic patients, a condition in which ...

Now the majority of U.S. infected patients are younger and HCV infections predominate in patients in the age group between 20 to 49 years with less than 10% of HCV patients being cirrhotic. This is ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

近年来，对脑损伤的研究引起了科学家们极大的关注，尤其是理解与人类神经性疾病相关的细胞和分子改变，在这一背景下，对不同临床生物标志物的研究就有望揭示引起大脑损伤的多种不同的病理学过程。近日，一篇发表在国际杂志 Chinese Medical ...

our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions ...

and said a filing in the lead indication of non-cirrhotic NASH with liver fibrosis hinged on a positive readout in MAESTRO-NASH. The new study seems to have delivered, hitting both its primary ...

前言“慢加急性肝衰竭（ACLF）主题月评”是中国慢（加急）性肝衰竭联盟受《国际肝病》编辑部邀请，制作的ACLF相关学术月评专栏。本专栏每月以ACLF某一特定领域为主题展开，旨在普及ACLF的概念及意义、帮助读者快速了解有关领域的进展。希望本专栏对无论 ...

Total paracentesis has also been shown to be as safe as repeated partial paracentesis and to shorten the period of hospitalization -- and may even be performed on an outpatient basis. [34] However ...